Thursday Morning’s Market Insights: Repros Therapeutics Inc (RPRX), Energy XXI Ltd (EXXI), Chipotle Mexican Grill, Inc. (CMG)

Repros Therapeutics Inc (NASDAQ:RPRX) is up 5% in pre-market trading, adding to their 175% increase yesterday after the company announced positive results from its Phase 2b study on Proellex, a drug that treats women suffering from uterine fibroids. Both the 12 mg and 6 mg doses of the drugs demonstrated a significant reduction in excessive menstrual bleeding in women with uterine fibroids compared to the placebo. According to the study, 100% of patients treated with Proellex reported a 100% median reduction in diary reports of menstrual bleeding product usage (PBAC), compared to a 25.4% reduction for those using the placebo. The company plans to meet with the FDA to discuss the end of its Phase 2 study as well as progressing the candidate into a Phase 3 study.

According to TipRanks, only 1 analyst rated the stock in the last 3 months with a Hold rating and $2.00 price target, marking an 11% downside from where shares last closed.

Energy XXI Ltd (NASDAQ:EXXI) is down a staggering 75% in pre-market trading after the oil company filed for Chapter 11 bankruptcy protection. Through its Chapter 11 restructuring, the company will eliminate over $2.8 billion in debt from its balance sheet. With a breakeven level of $60 per barrel of oil, the $40 a barrel oil prices as of late, down from $100 two years ago, have been weighing heavily on the company. Many other oil companies have suffered a similar plight, as over 40 others have attempted to settle with creditors last year. However, the company has $180 million in cash to support operations during the restructuring process.

Chipotle Mexican Grill, Inc. (NYSE:CMG) is up over 4% in pre-market trading following a rating by JP Morgan analyst John Ivankoe. The analyst upgraded the stock from Neutral to Overweight and increased his price target to $510 from $465. The analyst notes that CMG’s same store sales will improve after bottoming in Q1, indicating recovery after the E.Coli and Norovirus outbreak. The analyst predicts a full recovery for the brand in FY2017, very close to its FY2014 earnings. Ultimately, Ivankoe believes CMG  a “highly meaningful brand” that should regain customer confidence and trust. By FY2018, the analyst claims earnings growth will return to normal levels and predicts 20% + growth through FY2020.

According to TipRanks, 38% of analysts who have rated the company in the last 3 months are bullish on the stock. Another 38% remain on the sidelines, and 23% are bearish.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts